<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496286</url>
  </required_header>
  <id_info>
    <org_study_id>EP2014013</org_study_id>
    <nct_id>NCT02496286</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites</brief_title>
  <official_title>Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of intraperitoneal administration of&#xD;
      Bevacizumab to prevent the recurrence of malignant ascites. Ten patients will receive&#xD;
      intraperitoneal Bevacizumab 200 mg in 250 ml of normal saline for infusion every two weeks&#xD;
      for up to six weeks, or a maximum of three treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol describes a pilot study to assess whether intraperitoneal Bevacizumab infusion&#xD;
      is safe and improves the time to repeat paracentesis. In patients with non-draining malignant&#xD;
      peritoneal effusion, published data suggests that the average time to repeat paracentesis in&#xD;
      malignant ascites is 10-13 Days. The investigators' treatment will be considered potentially&#xD;
      efficacious if the median time to repeat paracentesis is greater than 14 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of Enrollment&#xD;
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Improvement</measure>
    <time_frame>14 days (+/-4 days)</time_frame>
    <description>Radiographic improvement in area of intraperitoneal collection will be evaluated (between the area of the intraperitoneal collection on the ultrasound pre-procedure and ultrasound evaluation on day 14 (+/-4 days).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume Output</measure>
    <time_frame>14 days (+/-4 days)</time_frame>
    <description>Change in volume output from baseline to day 14 (+/-4 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>14 days (+/-4 days)</time_frame>
    <description>Adverse events will be judged possibly or probably related to intraperitoneal Bevacizumab infusion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Malignant Ascites</condition>
  <arm_group>
    <arm_group_label>Eligible patients requiring paracentesis for symptom control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraperitoneal Bevacizumab</intervention_name>
    <description>Bevacizumab 200mg diluted in 250 ml of normal saline</description>
    <arm_group_label>Eligible patients requiring paracentesis for symptom control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients will be included in the case of:&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2&#xD;
&#xD;
               -  Participants must be 18 years of age or older&#xD;
&#xD;
               -  Have ascites of malignant disease&#xD;
&#xD;
               -  Have symptoms related to ascites&#xD;
&#xD;
               -  Ascites Index above 0.05 (AI ˃ 0.05)&#xD;
&#xD;
               -  Be an English speaking patient or have an interpreter available&#xD;
&#xD;
               -  Be able to understand and comply with all study requirements and the implications&#xD;
                  of off-label use of intraperitoneal Bevacizumab&#xD;
&#xD;
               -  Have had at least two paracentesis within the last 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded in the case of:&#xD;
&#xD;
               -  Ascites due to non-malignant cause&#xD;
&#xD;
               -  Concurrent treatment with systemic chemotherapy that has a realistic chance of&#xD;
                  controlling the ascites&#xD;
&#xD;
               -  Concurrent treatment with intraperitoneal Bevacizumab&#xD;
&#xD;
               -  life expectancy of less than 2 weeks&#xD;
&#xD;
               -  A history of bowel perforation or fistula&#xD;
&#xD;
               -  Symptoms or signs suggestive of bacterial peritonitis&#xD;
&#xD;
               -  Child's C cirrhosis&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Surgery within 28 days of catheter treatment&#xD;
&#xD;
               -  Evidence of coagulopathy&#xD;
&#xD;
               -  Symptoms suggestive of bowel obstruction&#xD;
&#xD;
               -  Major surgery, open biopsy or significant traumatic injury within seven (7) days&#xD;
                  of first study drug--including neurosurgery.&#xD;
&#xD;
               -  Inability to complete informed consent process and adhere to the protocol&#xD;
                  treatment plan and follow-up requirements.&#xD;
&#xD;
               -  Concurrent severe illness such as active infection, or psychiatric illness/social&#xD;
                  situations that would limit safety and compliance with study requirements&#xD;
&#xD;
               -  Patients who are pregnant or lactating (females of childbearing potential must&#xD;
                  have a negative pregnancy test prior to participation)&#xD;
&#xD;
               -  Patients with pre-existing 3 + or greater urine dipstick reading proteinuria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eastern Regional Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Necessary paracentesis for symptom control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

